Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.57 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.53 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | GRM1 | Q13255 | 9/20 | 0.48 |
| ▸ | GRM5 | P41594 | 8/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.46 |
| ▸ | CDK7 | P50613 | 1/20 | 0.45 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.45 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31706789 | 0.88 | NAMPT (0.55) | NAMPTPDK4USP30GRM1GRM5 | |
| SCHEMBL22324970 | 0.88 | NAMPT (0.55) | NAMPTPDK4USP30GRM1GRM5 | |
| SCHEMBL3169756 | 0.88 | PDK4 (0.55) | NAMPTPDK4USP30GRM1GRM5 | |
| SCHEMBL29924834 | 0.88 | PDK4 (0.55) | NAMPTPDK4GRM1GRM5JAK1 | |
| SCHEMBL31747276 | 0.87 | PDK4 (0.54) | NAMPTPDK4GRM1GRM5JAK1 | |
| SCHEMBL7831576 | 0.84 | PDK4 (0.58) | NAMPTPDK4GRM1GRM5SOS1 | |
| SCHEMBL1274660 | 0.83 | PDK4 (0.51) | NAMPTPDK4GRM1GRM5JAK1 | |
| SCHEMBL1364792 | 0.83 | PDK4 (0.57) | NAMPTPDK4GRM1GRM5SOS1 | |
| SCHEMBL29914645 | 0.83 | PDK4 (0.57) | NAMPTPDK4GRM1GRM5SOS1 | |
| SCHEMBL2811392 | 0.83 | PDK4 (0.60) | NAMPTPDK4USP30GRM1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062317-A1 | MEDICINAL USE OF RECEPTOR LIGANDS | 7TM PHARMA A/S (DK) | 2009-03-05 | — | — | US | disclosed |
| US-20090062317-A1 | MEDICINAL USE OF RECEPTOR LIGANDS | 7TM PHARMA A/S (DK) | 2009-03-05 | — | — | US | disclosed |
| US-20090062317-A1 | MEDICINAL USE OF RECEPTOR LIGANDS | 7TM PHARMA A/S (DK) | 2009-03-05 | — | — | US | disclosed |
| EP-1778670-A2 | MEDICINAL USE OF RECEPTOR LIGANDS | 7TM Pharma A/S (DK) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006010446-A2 | MEDICINAL USE OF RECEPTOR LIGANDS | 7TM PHARMA A/S (DK) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062317-A1 | MEDICINAL USE OF RECEPTOR LIGANDS | MCHR1, MCHR2, MC1R | NAMPT 3849/4885PDK4 1915/4885USP30 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.